High Tide subsidiary NuLeaf Naturals intends to participate in a new U.S. Medicare CBD pilot program as a supplier, potentially driving growth in the Company's U.S. CBD business.
Key takeaways
NuLeaf Naturals intends to pursue participation in the CMS Innovation Center's BEI pilot program as a supplier of hemp-derived CBD products.
The pilot program launched April 1, 2026, allowing Medicare beneficiaries to receive eligible CBD products at no cost, up to US$500 per year.
CEO Raj Grover stated the program has the potential to become a meaningful growth driver for High Tide's U.S. CBD business.
NuLeaf possesses cGMP-certified and FDA-registered facilities, positioning it to meet the program's quality and compliance requirements.
The program is available to participants in the ACO REACH Model and Enhancing Oncology Model, with expansion to the LEAD Model in 2027.